Diabetes

Top articles of the week from The American Journal of Pharmacy Benefits.

Eighty percent of patients with diabetes have uncontrolled blood sugars, blood pressures, or cholesterol.

The Journal of Continuing Education in the Health Professions has published a study that assessed the effect of interprofessional education (IPE) on the quality of diabetes care.

The discussions at the Advisory Committee meeting were based on data from the LEADER trial.

Efficacy of empagliflozin (Jardiance) may be limited to clinical trial population.

Top news of the day from across the health care landscape.

Functional high-intensity training may benefit patients with type 2 diabetes.

Experimental biopolymer observed to maintain blood glucose levels in monkeys for 2 weeks.

Pharmacists help underserved adults with uncontrolled type 2 diabetes who live in rural areas.

A telemedicine diabetes program was well received by patients and effective at improving patient outcomes, according to a study published online in the North Carolina Medical Journal.

Top news of the day from across the health care landscape.

BioChaperone Combo integrates Lantus and Humalog.

This article highlights 5 published case reports that document unusual drug overdoses.

This article will describe the unusual discovery of 5 commonly prescribed medications, many of which occurred through serendipitous events.

Results from the EMPA-REG OUTCOME trial suggests empagliflozin (Jardiance) has potential in the treatment of chronic kidney disease.

Closed-loop systems help diabetes patients achieve blood glucose control, according to a presentation at the American Diabetes Association’s 77th Scientific Sessions.

Transition care may improve diabetes outcomes, according to a study presented at the American Diabetes Association’s 77th Scientific Sessions.

American Diabetes Association’s 77th Scientific Sessions highlight benefits of glucose monitoring.

Adolescents and young adults with type 1 diabetes benefit from a structured transition program when changing from pediatric to adult diabetes care.

These data, from the integrated analysis of the CANVAS and CANVAS-R trials, demonstrated the CV safety of canagliflozin (P

Results of this trial were presented at the ADA Meeting in San Diego.

REMOVAL trial results presented at the American Diabetes Association’s 77th Scientific Sessions.

Results of the ODYSSEY study presented at the American Diabetes Association’s 77th Scientific Sessions.

Metformin may be an effective long-term strategy worthy of adding to an individual’s diabetes care plan to reduce the risk of heart disease in adults with type 1 diabetes.

Sotagliflozin effective in treating patients with type 1 diabetes.